Anebulo Pharmaceuticals Inc. (ANEB) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Anebulo Pharmaceuticals Inc. (ANEB:NASDAQ), powered by AI.

Current Price
$0.39
P/E Ratio
-1.6
Market Cap
13M
Sector
Healthcare
What is the Anebulo Pharmaceuticals Inc. stock price forecast?

Anebulo Pharmaceuticals Inc. is currently trading at $0.39. View real-time AI analysis on Alpha Lenz.

What is Anebulo Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Anebulo Pharmaceuticals Inc. on Alpha Lenz.

What is Anebulo Pharmaceuticals Inc.'s P/E ratio?

Anebulo Pharmaceuticals Inc.'s P/E ratio is -1.6.

Anebulo Pharmaceuticals Inc.

NASDAQ · ANEB
$0.39-0.01(-2.50%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Anebulo Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Anebulo Pharmaceuticals Inc. trades at a P/E of -1.6 (undervalued) with modest ROE of -109.7%.

Ask for details

Company Overview

Anebulo Pharmaceuticals Inc. is a biopharmaceutical company focused on developing novel treatments for patients suffering from ailments with few current medical solutions. The company's primary mission is to innovate and advance the development of therapeutic solutions targeting specific unmet medical needs, particularly within the realm of neurology and cannabinoid-related treatments. A noted area of impact for Anebulo Pharmaceuticals is its work on mitigating the effects of cannabinoid overdose and addressing conditions related to neurological impairments. The company leverages cutting-edge scientific research and clinical trials to create medications that can significantly enhance patient outcomes. In the financial market, Anebulo Pharmaceuticals represents an important player in the life sciences sector, driving forward advancements that hold the potential for significant clinical and economic implications. As a company engaged in highly specialized pharmaceutical development, its activities and breakthroughs are closely watched by healthcare professionals, regulatory bodies, and financial analysts interested in the intersection of biopharma innovation and market potential.

CEOMr. Richard Anthony Cunningham
SectorHealthcare
IndustryBiotechnology
Employees2

Company Statistics

FY 2025

Profile

$13.19MMarket Cap
$0.00Revenue
0.00Shares Out
2Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-1.55P/E
1.13P/B
N/AEV/Sales
-0.19EV/EBITDA
-2.08P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-104.63%ROA
-109.69%ROE
-99.92%ROIC

Financial Health

$11.63MCash & Cash Equivalents
$-11.14MNet Debt
4.18%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Anebulo Pharmaceuticals Inc. (ticker: ANEB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 2 employees. Market cap is $13M.

The current price is $0.39 with a P/E ratio of -1.55x and P/B of 1.13x.

ROE is -109.69%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Anebulo Pharmaceuticals Inc. (ANEB) Stock Forecast 2026 $0.39 — Price, Financials & Analyst Targets | Alpha Lenz